Gene
ERBB4
ERBB4 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (41), Actionable biomarkers (4), Trial mentions (13), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention ERBB4. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 7 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 30 of 11,460 | 0.26% |
| 2022 | 1 of 8,285 | 0.01% | 28 of 13,598 | 0.21% |
| 2021 | 1 of 8,692 | 0.01% | 31 of 15,045 | 0.21% |
| 2020 | 0 of 7,640 | 0.00% | 25 of 14,459 | 0.17% |
| 2019 | 0 of 7,300 | 0.00% | 23 of 12,159 | 0.19% |
| 2018 | 1 of 6,927 | 0.01% | 15 of 11,854 | 0.13% |
| 2017 | 1 of 6,558 | 0.02% | 27 of 11,595 | 0.23% |
Showing 10 of 37 years.
Assay-provider ledger (41)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Promega | Reagent supplier | Clinical validationAnalytical validation | 2 | November 08, 2021 |
| Thermo Fisher | Reagent supplier | Analytical validation | 1 | November 08, 2021 |
| UPMC Molecular & Genomic Pathology (MGP) Laboratory | Not a company | Clinical validationAnalytical validation | 1 | January 01, 2020 |
| Advanced Cell Diagnostics | Reagent supplier | Clinical validationAnalytical validation | 1 | July 01, 2018 |
| Avacta Life Sciences Ltd | Reagent supplier | Analytical validation | 1 | June 15, 2018 |
Showing 5 of 41 assay-provider companies.
Actionable biomarkers (4)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| ERBB4 (H809G) | LAPATINIB | responsive | breast adenocarcinoma | Cancer Genome Interpreter |
| ERBB4 (E317K,E452K,R544W,R393W,E872K) | LAPATINIB | response-associated | cutaneous melanoma | Cancer Genome Interpreter |
| ERBB4 fusion | AFATINIB | response-associated | lung adenocarcinoma | Cancer Genome Interpreter |
| ERBB4 fusion | LAPATINIB | response-associated | lung adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (13)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT03452774 | Trial eligibility (AACT) |
| NCT01211483 | Trial eligibility (AACT) |
| NCT04872985 | Trial eligibility (AACT) |
| NCT02350712 | Trial eligibility (AACT) |
| NCT02134015 | Trial eligibility (AACT) |
Showing 5 of 13 trial mentions.
Target-disease associations (633)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| ACTH-Producing Pituitary Gland Adenoma | cancer or benign tumor | Cancer Gene Census |
| Abelson tyrosine-protein kinase 2 measurement | measurement | GWAS credible sets |
| Abnormal nasolacrimal system morphology | phenotype | GWAS credible sets |
| Abnormality of the gastrointestinal tract | phenotype | GWAS credible sets |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
Showing 5 of 633 associations.
Vendor sourcing (50)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v4.1.0 dataset. Predicted Consequence/Location: Missense variant Therefore, this variant is classified as VUS accor... | View ClinVar record SCV007609627.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.119_120delCT (p.S40*) alteration, located in exon 2 of the ERBB4 gene, consists of a deletion of 2 nucleotides from position 119 to 120, causing the se... | View ClinVar record SCV000741212.5 |
| Astrazeneca Plc | Trial collaborator | Named in trial exclusion criteriaTrial eligibility criteria | : * Any treatment with investigational drugs within 30 days prior to receiving the first dose of investigational treatment. * History of another malignancy ... | View trial NCT02450656 |
| Astrazeneca Plc | Trial collaborator | Mentioned in trial textTrial free-text mention | HER4 | View trial NCT02450656 |
| Boehringer Ingelheim (Germany) | Trial collaborator | Named in trial exclusion criteriaTrial eligibility criteria | : * Any treatment with investigational drugs within 30 days prior to receiving the first dose of investigational treatment. * History of another malignancy ... | View trial NCT02450656 |
Showing 5 of 50 sourcing records.
Trial-cited literature (324)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Single Ascending-Dose Study of Selective ErbB4 Agonist JK07 in Heart Failure With Reduced Ejection Fraction. | JACC. Basic to translational science | 2025 | 4 |
| Tumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02). | Signal transduction and targeted therapy | 2025 | 2 |
| Effects of acetazolamide combined with remote ischemic preconditioning on risk of acute mountain sickness: a randomized clinical trial. | BMC medicine | 2024 | 16 |
| Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis. | Translational oncology | 2024 | 15 |
| Transcriptomics of Subcutaneous Tissue of Lipedema Identified Differentially Expressed Genes Involved in Adipogenesis, Inflammation, and Pain. | Plastic and reconstructive surgery. Global open | 2024 | 11 |
Showing 5 of 324 papers.
Protein variant mentions (21)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.C759T | 1 | 2015 | PMID 26572169 |
| p.G1272R | 1 | 2015 | PMID 25741868 |
| p.G219S | 1 | 2015 | PMID 25741868 |
| p.G571A | 1 | 2009 | PMID 19718025 |
| p.H374Q | 1 | 2015 | PMID 25741868 |
Showing 5 of 21 variants.
Literature-extracted relations (26)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| AFATINIB | Chemical | negative_correlate |
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations. | 2023 |
| AFATINIB | Chemical | negative_correlate |
Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors. | 2014 |
| Flutamide | Chemical | negative_correlate |
Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence. | 2014 |
| AFATINIB | Chemical | negative_correlate |
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. | 2013 |
| LAPATINIB | Chemical | negative_correlate |
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. | 2009 |
Showing 5 of 26 relation assertions.
Organizations publishing (419)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 17 | 2008 to 2023 |
| The University of Texas System | Academic | 12 | 2010 to 2023 |
| Harvard Medical School | Academic | 11 | 2010 to 2022 |
| Government of the United States of America | Government | 10 | 2009 to 2022 |
| Fudan University Shanghai Cancer Center | Hospital | 9 | 2011 to 2023 |
Showing 5 of 419 organizations.
Where ERBB4 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- psychiatric disorder
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
542 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.